CTMC Began Pivotal TIL Manufacturing in Houston

The Houston-based company has launched a partner program for tumor-infiltrating lymphocyte therapy production.

Updated on Oct. 1, 2026 in Biotech

Isometric editorial illustration of a stainless steel bioreactor vessel in a sterile clinical laboratory environment. — CTMC has commenced pivotal-stage manufacturing for its patient-specific tumor-infiltrating lymphocyte therapy program at its facilities in Houston. AI Illustration. Upload story photo >

Live Poll

Do you trust private-public partnerships to accelerate the development of new cancer therapies?

CTMC has commenced pivotal-stage manufacturing for a partner tumor-infiltrating lymphocyte (TIL) program at its Houston facilities. The process integrates a proprietary platform and digital tracking systems to support patient-specific therapies.

Why it matters

This advancement aims to reduce process variability and expand the range of starting materials available for engineered TIL therapies. By integrating regulatory, quality, and manufacturing systems, the platform seeks to improve scalability for cancer treatments.

The proprietary manufacturing process produces engineered TILs in under 30 days using a closed-system approach. The platform incorporates TR-41, a 4-1BB agonist for cell activation, and TR-56, a defined feeder-cell line.

The players

CTMC

An organization based in the Texas Medical Center that focuses on cell therapy development and manufacturing.

Cancer Prevention and Research Institute of Texas

A state agency that provided funding support for the development of the company's TIL platform.

The details

CTMC uses an integrated model that combines cell therapy development with GMP manufacturing and digital chain-of-identity solutions powered by autoloMATE. This purpose-built system is designed to provide full traceability throughout the production of patient-specific therapies.

October 1, 2026: CTMC announced the start of pivotal-stage manufacturing.

The Tech Race

This development follows a trend established by the Cancer Prevention and Research Institute of Texas research grant program to boost local biotech infrastructure. It positions the firm within a broader competitive push to modernize cell therapy production through digitalization and closed-system automation.

The implementation of standardized manufacturing platforms can lead to more consistent and reliable cancer treatment options for patients. By automating chain-of-custody tracking, the system also reduces the risk of errors in the production of patient-specific medical therapies.

The takeaway

The move toward automated, closed-loop manufacturing marks a shift in how specialized cell therapies move from the lab to clinical use. By shortening production windows, developers can improve the efficiency of delivering complex personalized cancer treatments.